As antibody-drug conjugates (ADCs) advance in precision oncology, diagnostics play a vital role in identifying eligible patients, validating biomarkers and supporting regulatory approval.
Companion diagnostics (CDx) enable targeted therapies by confirming the presence of specific biomarkers, helping to match patients with the most appropriate treatments. A well-integrated diagnostic strategy ensures that ADC development is optimized for clinical success and regulatory readiness.
In this webinar, the expert speaker will explore the expanding role of precision diagnostics in ADC development and how strategic diagnostic partnerships can help streamline biomarker validation, patient selection and regulatory alignment.
Register for this webinar today to explore the critical role of companion diagnostics in antibody-drug conjugate development.
Speaker
Dr. Yuri Fesko, MD, Chief Medical Officer, Quest Diagnostics
Located in the New York City Metropolitan Area, Dr. Yuri Fesko is a board-certified Medical Oncologist and the Chief Medical Officer at Quest Diagnostics. With over two decades of experience in clinical practice and medical leadership, Dr. Fesko leads the company’s medical affairs, clinical development, and strategic medical initiatives – particularly in oncology diagnostics and precision medicine.
He has pioneered innovative diagnostic solutions, including the development of the next-generation sequencing panel and decentralized clinical trials, enhancing patient care and healthcare affordability. An active speaker and published author, Dr. Fesko’s work continues to influence global healthcare advancements.
Message PresenterWho Should Attend?
This webinar is ideal for professionals in the pharmaceutical industry, particularly oncology researchers involved in ADC drug development and precision medicine. Key attendees include:
- Pharma industry professionals focused on ADCs
- Clinical researchers and diagnostic development teams engaged in clinical trials and biomarker research
- Decision-makers and strategists seeking to enhance their understanding of biomarker-driven therapies and their impact on drug development
What You Will Learn
Attendees will learn about:
- Key considerations in antigen validation and patient selection
- The role of CDx in ADC programs
- How to support biomarker-driven therapy development
Xtalks Partner
Quest Diagnostics
When you choose Quest Diagnostics as your partner in BioPharma Services, you get more than lab testing. Access the reach, expertise, and renowned quality of Quest Diagnostics for every milestone of your program—from R&D consulting through clinical trials, companion diagnostic development, commercialization, and post-launch surveillance. Together we have the power to deliver better outcomes.
You Must Login To Register for this Free Webinar
Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.
Create Account